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Results: Ninety-ﬁve patients were included in this study. Seventy ﬁve 
underwent EPP, 9 P/D, and 11 P. Of these 95 patients with ﬁnal diag-
nosis of MPM, 80 (84.3%) were classiﬁed as epithelial and 15 (15.7%) 
as biphasic. Among the 87 patients classiﬁed as MPM of epithelial type 
after the initial thoracoscopy procedure, 75 (86.2%) were conﬁrmed as 
a true histological diagnosis and 12 (13.7%) were found to be biphasic 
at ﬁnal diagnosis. One patient with a biphasic type at initial diagnostic 
procedure was found as epithelial type after surgical histological as-
sessment. The sensitivity and speciﬁcity values of epithelial diagnosis 
after thoracoscopy were 94 % and 25 %, respectively, with a positive 
predictive value of 86 % and a negative predictive value of 37 %. At 
contrary, the sensitivity and speciﬁcity values of biphasic diagnosis 
after thoracoscopy were 20 % and 98 %, respectively, with a positive 
predictive value of 75 % and a negative predictive value of 87 %.
Conclusions: Thoracoscopy pleural biopsy is conﬁrmed as the cor-
nerstone for the diagnosis of MPM. However this procedure is less 
efﬁcient in diagnosing histological type as epithelial versus biphasic 
subtype.
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Background: Thymic neuroendocrine tumors (TNET) are rare neo-
plasms. We report the clinical and pathological features of 8 TNET.
Results: There were 2 women and 6 men (mean age of 54.5 years), 
presenting with local symptoms (cough, dyspnea, thoracic pain) in 4 
cases, bone metastases in 1 case and Cushing syndrome in 2 cases. 
One patient was diagnosed incidentally. None of them had history of 
MEN. The tumors were divided according to histopathologic features 
into high-grade (n=7) and low-grade (n=1) types. Staging revealed 
two stages I, three stages II, one stage III and two stages IV tumors. 
Six patients underwent surgery and complete excision was possible 
in 3 cases. Five patients had received postoperative radiotherapy. Six 
patients had received chemotherapy (at ﬁrst to fourth lines). Follow-up 
was available in all patients. Three patients died of distant metastasis 
(at 13 and 52 months). Three patients are alive with disease (at 73 and 
103 months) and two are alive and disease-free (at 10 and 81 months).
Conclusions: Patients with TNET are considered to have a worse 
prognosis than patients with pulmonary carcinoid. According to the 
5 years-survival (>50%) in our study, prognosis may be better than 
reported in the literature. 
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Background: There is little published data on chemotherapy in pul-
monary carcinoid tumors. The objective of this retrospective study is 
to evaluate the response rates to different chemotherapy regimens in 
atypical pulmonary carcinoid patients.
Methods: Patients with pulmonary neuroendocrine tumors treated at 
our institution were identiﬁed. The medical records of patients with 
conﬁrmed diagnosis of atypical pulmonary carcinoid were reviewed for 
the presence of progressive disease, treatment with chemotherapy, and 
response to this treatment. 
Results: 37 pts with progressive atypical pulmonary carcinoid tumor 
who were treated with chemotherapy were identiﬁed. Of these, 2 
patients received induction chemotherapy with cisplatin and etoposide 
(PE) before surgery, to which one had a partial response and the other 
had stable disease. One patient with unresectable pulmonary carcinoid 
tumor progressed under PE regimen. 
34 metastatic patients (liver or bone metastasis) received various 
ﬁrst-line chemotherapy regimens: 17 patients were treated with 5-FU 
and streptozotocin-based regimen (FS), 9 patients with PE-based 
chemotherapy, and 8 patients with other associations combining 5-FU 
or doxorubicin. There were overall 11 partial responses (PR), 11 stable 
disease (SD), and 12 progressive disease (PD). 
The overall response rate to ﬁrst-line chemotherapy was 32%. FS com-
bination resulted in 6/17 PR (35%) and 5/17 SD (29%). PE regimen 
resulted in 3/12 PR (25%) and 4/12 SD (33%) in the whole population, 
2/9 PR (22%) and 3/9 SD (33%) in metastatic patients. 
22 patients received a second-line chemotherapy resulting in 2 PR, one 
PR to 5-FU and dacarbazine regimen, the other to FS combination; 10 
patients achieved a SD of whom 5 were treated with FS-based regimen 
and 4 with 5-FU drug. 3 PE regimen resulted in PD. 7 patients received 
a third-line chemotherapy resulting in 1 PR to 5-FU and 3 SD under 
1 FS association, 1 5-FU and dacarbazine regimen, and 1 dacarbazine 
and interferon combination. Prolonged stable disease were observed 
and 4 patients then could receive chemoembolization.
Conclusion: This retrospective review of 37 patients with atypi-
cal pulmonary carcinoid tumors shows a response rate to ﬁrst-line 
chemotherapy of 32%. More objective responses and prolonged stable 
diseases were observed in metastatic patients treated with 5-FU and 
streptozotocin-based regimen.
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Introduction: It is generally considered that survival in malignant 
mesothelioma is less than one year. In the largest study so far on the 
disease, the Pemetrexed Study in the US, where 448 patients were 
randomized to either Pemetrexed + Cisplatin or to Cisplatin alone, the 
survival in the Pemetrexed arm was 12 months versus 9 months in the 
cisplatin arm alone. Many other studies have come to similar results. 
However, the experience of the Nordic Mesothelioma Groups is differ-
ent We here present some data from the last study, where 184 patients 
with malignant mesothelioma, all stages, PS 0-2, all ages, were treated 
with a combination of Liposomized Doxorubicine, Carboplatin, and 
Gemcitabine.
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Results: In 147 patients, subtyping of the mesothelioma and follow-up 
until death or at least 18 months were available. 73 % (108 patients) 
were of the epithelial subtype. Their median survival was 15 months; 
44% survived 18 months, 25% 2 years, and 9 % 3 years. Two patients 
are still alive after 5 years. 14 were staged as Stage IV (i.e. metasta-
ses outside the hemithorax) when included in the study; their median 
survival was 11 months, 2 have survived 2 years, and one is still alive 
at 61 months. 14% had a mixed subtype; their mean survival was 8 
months, 28 % survived 1 year, 19 % 18 months, and none 2 years. For 
the 12 % with sarcomatous subtype, mean survival was 4 months, 11% 
survived 1 year, and there was no 2-year survivor.
Discussion: The survival was considerably better than in most other 
studies. The reason is probably not that the treatment is superior 
but rather a different selection. Traditionally, surgery has been used 
only very sparingly in the Nordic countries; in countries where this 
is performed, patients with the best PS and the lowest stages will be 
selected for surgery. Thus, generally only patients in worse conditions 
will be treated with chemotherapy. This is important to remember when 
surgical results are evaluated. It is also obvious that subtype is more 
important than stage. 
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Background: Thymoma is an uncommon neoplasm that is derived 
from the epithelial cells of the thymus. Carcinogenesis of thymic 
epithelial tumor has not been clear yet. Our previous study showed 
high frequency of p53 protein expression in thymic carcinoma but not 
in thymoma. Recent reports demonstrated that epigenetic inactivation 
of certain tumor suppressor genes by aberrant promoter methylation 
is frequently observed in cancers and that seems to play an important 
role in carcinogenesis. We examined aberrant methylation patterns of 
5 cancer-related genes in 28 thymic epithelial tumors to clarify their 
carcinogenesis. 
Materials and Methods: We examined aberrant methylation of 5 
cancer-related genes (DAP-K, p-16, MGMT, RAR-β and HPP1 genes) 
in 20 thymomas, 7 thymic carcinomas and one thymic carcinoid that 
we resected between 1985 and 2006 in Tokushima University Hospital. 
There were 1 type A, 6 type AB, 8 type B1, 3 type B2, 2 type B3 thmo-
mas, 7 thymic carcinoma and one carcinoid according to World Health 
Organization histologic classiﬁcation. Masaoka’s clinical staging was 9 
cases in stage I, 7 cases in Stage II, 6 cases in stage III, 5 cases in stage 
IV. The genes selected DAP-K, p-16, MGMT, RAR-β and HPP1 genes 
that were previously described as aberrantly methylated in lung car-
cinoma or malignant mesothelioma. Samples were frozen and stored. 
Genomic DNA was subjected to bisulﬁte treatment. PCR ampliﬁcation 
was done with bisulﬁte-treated DNA, using speciﬁc primer sequences 
for the methylated and unmethylated forms of the genes. PCR products 
were loaded on agarose gels.
Results: In thymoma, aberrant methylation was detected in 3 of 13 
(23.1%) for DAP-K, 1 of 14 (7.1 %) for p-16, 1 of 16 (6.3%) for 
MGMT, 1 of 10 (10%) for RAR-β and 1 of 16 (6.3%) for HPP1. Six 
(29%) of 21 thymomas had aberrant methylation of cancer-related 
genes (1 case in type A, 1 case in type AB and 3 cases in type B1) (3 
cases in stage I and 3 cases in stage II). Methylation was 5 cases in one 
gene and one case in 2 genes. On the other hand, in thymic carcinoma, 
aberrant methylation was detected in 2 of 5(40%) for DAP-K, 0 of 6 (0 
%) for p-16, 5 of 7 (71.4%) for MGMT, 0 of 6 (0%) for RAR-β and 3 
of 7 (42.9%) for HPP1. Six (86%) of 7 thymic carcinomas had aberrant 
methylation. Methylation was 3 cases in one gene, 2 cases in 2 genes 
and one case in 3 genes.
Conclusion: Aberrant methylation were more frequent in thymic car-
cinoma (86%) than in thymoma (29%). And half of thymic carcinoma 
had methylation of several genes. In thymoma, methylation of cancer-
related genes was not related to clinical stage.
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Background: Patients with malignant pleural mesothelioma (MPM) 
are rarely diagnosed at their early stages. It is not fully recognized what 
is the earliest event in the development of MPM and how it progresses. 
The aim of this study was to elucidate the early microscopic changes 
of MPMs that were removed surgically and conﬁrmed to be MPM by 
histological and immunohistochemical examination.
Methods: Fourteen cases with MPM who underwent exrapleural pneu-
monectomy between 1995 and 2006 were investigated. We arbitrarily 
deﬁned mesothelioma at early stage as tumor whose thickness was 
equal to or less than 6mm. We used a panel of immunohistochemical 
markers to conﬁrm the diagnosis of mesothelioma. 
Reults: The age of the patients ranged from 40 to 66 and all were 
male. Four were with Stage IB, ﬁve with Stage II, ﬁve with Stage III, 
and one with Stage IV mesothelioma. Seven of these patients were 
designated at early stage according to our deﬁnition. Five cases were 
epithelioid mesothelioma, one was biphasic, and one was sarcomatoid. 
There was pleural cavity between parietal and visceral pleura and the 
surface of the lung looked normal, but both pleura were fused focally 
in some cases. There was no visible nodule in these cases, but white 
ﬂat maculae or small yellow nodules were observed at the surface of 
the pleura in some of the cases. Microscopically mesothelioma cells 
proliferated both on the parietal and visceral pleura and invaded into it. 
They proliferated in solitary, trabecular, papillary, or solid patterns in 
epithelioid mesothelioma. The lesions were discontinuous and multifo-
cal. Microscopic invasion into the lung and/or diaphragm was observed 
after evaluation of many blocks even in MPM with clinical stage I. 
Interlobar pleura and interlobular connective tissue was also invaded by 
the mesothelioma cells. The size of the lesion in the parietal pleura was 
larger than that in the visceral pleura. In an extremely early case, the 
lesions existed mainly in the parietal pleura, but a few foci of visceral 
pleural invasion were observed. Seeding of the mesothelioma cells on 
the tract of thoracoscopy was observed in three cases, and recurrence 
occurred in four of seven early stage MPMs. One-year and two-year 
overall survival rates for the early stage mesothelioma were 100% and 
